Research Article
Utility of Inflammatory Markers in Predicting Hepatocellular Carcinoma Survival after Liver Transplantation
Table 1
Patient characteristics and correlation with inflammatory markers.
| | NLR | dNLR | LMR | PLR | <5 | ≥5 | P | <3 | ≥3 | P | <3.45 | ≥3.45 | P | <150 | ≥150 | P | N | 122 | 38 | | 135 | 25 | | 98 | 62 | | 133 | 27 | |
| Male | 78.7% | 76.3% | 0.76 | 78.5% | 76% | 0.78 | 78.6% | 77.4% | 0.86 | 78.9% | 74.1% | 0.58 |
| Age (Year) mean ± SD | 57±8 | 58±7 | 0.76 | 57±8 | 57±8 | 0.92 | 58±7 | 57±8 | 0.54 | 57±8 | 58±7 | 0.80 |
| White race | 74.6% | 84.2% | 0.22 | 75.6% | 84% | 0.36 | 78.6% | 74.2% | 0.52 | 76.7% | 77.8% | 0.90 |
| HCV etiology | 75.4% | 71.1% | 0.59 | 74.1% | 76% | 0.84 | 70.4% | 80.6% | 0.15 | 74.4% | 74.1% | 0.97 |
| MELD, mean ± SD | 12±7 | 17±10 | 0.004 | 12±7 | 18±11 | 0.02 | 16±8 | 9±6 | 0.003 | 13±8 | 12±8 | 0.57 |
|
|
dNLR, derived neutrophil lymphocyte ratio; HCV, hepatitis C virus; LMR, lymphocyte monocyte ratio; MELD, Model for End Stage Liver Disease; NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio.
|